Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
Citius Oncology, Inc. (CTOR) reported cash provided by (used in) financing activity, including discontinued operation of $15.13M in Q4 2025.
How has Citius Oncology, Inc.'s cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Citius Oncology, Inc.'s cash provided by (used in) financing activity, including discontinued operation increased by 298.9% year-over-year, from $3.79M to $15.13M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.